Monoamine neurocircuitry in depression and strategies for new treatments

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 54-63

  Hamon, Michel ^a   Blier, Pierre ^b  

^a INSERM   (France)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

FMRI; Major depressive disorder; Monoamine neurocircuitry; Multimodal antidepressants; Serotonin receptors

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMFEBUTAMONE; AMITIFADINE; ANTIDEPRESSANT AGENT; DOPAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LUAA 21004; MIRTAZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PINDOLOL; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; VORTIOXETINE;

COGNITION; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC SYSTEM; DRIVE; DRUG DESIGN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EMOTION; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; HUMAN; LIMBIC SYSTEM; MENTAL STRESS; MONOAMINERGIC SYSTEM; MOOD; MOTIVATION; NERVE CELL NETWORK; NERVE TRACT; NEUROTRANSMISSION; NONHUMAN; REVIEW; SELF CONTROL; THALAMUS; UNSPECIFIED SIDE EFFECT;

5-HT; 5-HYDROXYTRYPTAMINE, SEROTONIN; BDNF; BRAIN DERIVED NEUROTROPHIC FACTOR; CA; CATECHOLAMINES; CENTRAL NERVOUS SYSTEM; CG25; CNS; CO-MED; COMBINING MEDICATIONS TO ENHANCE DEPRESSION OUTCOMES; CORTICOTROPIN-RELEASING HORMONE; CRH; DA; DAT; DOPAMINE; DOPAMINE TRANSPORTER; DORSAL RAPHE NUCLEUS; DRN; FMRI; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAM-D; HAMILTON DEPRESSION RATING SCALE; HPA; HYPOTHALAMO-PITUITARY-ADRENAL (AXIS); LCSPT; LIMBIC-CORTICAL-STRIATAL-PALLIDAL-THALAMIC (CIRCUITS); MADRS; MAGNETIC RESONANCE IMAGING; MAJOR DEPRESSIVE DISORDER; MAOIS; MDD; MIXED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS; MONOAMINE NEUROCIRCUITRY; MONOAMINE OXIDASE INHIBITORS; MONTGOMERY-ÅSBERG DEPRESSION RATING SCALE; MRI; MULTIMODAL ANTIDEPRESSANTS; N-METHYL-D-ASPARTATE; NE; NET; NMDA; NOREPINEPHRINE; NOREPINEPHRINE TRANSPORTER; NRIS; OFC; ORBITOFRONTAL CORTEX; PET; POSITRON EMISSION TOMOGRAPHY; PRL; PROLACTIN; QIDS-SR; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY: SELF RATED; REGIONAL HOMOGENEITY; REGIONS OF INTEREST; REHO; ROI; SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS; SELECTIVE SEROTONIN REUPTAKE INHIBITORS; SEROTONIN RECEPTORS; SEROTONIN TRANSPORTER; SERT; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SNRIS; SR; SSRIS; SUBGENUAL CINGULATE (BRODMANN AREA 25); SUSTAINED RELEASE; TCAS; TPH2; TRICYCLIC ANTIDEPRESSANTS; TRYPTOPHAN HYDROXYLASE-2; VENTRAL TEGMENTUM AREA; VTA;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FUNCTIONAL NEUROIMAGING; HUMANS; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY; NEURAL PATHWAYS; SYNAPTIC TRANSMISSION;

EID: 84878358579     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.04.009     Document Type: Review

References (133)

1. 1A receptor gene expression as a new target for antidepressant therapy. Front Neurosci 2010, 4:1-7.
2. Albert P.R., Le François B., Millar A.M. Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. Mol Brain 2011, 4:21.
3. Alvarez E., Perez V., Dragheim M., Loft H., Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2011, 15:589-600.
4. Anacker C., Zunszain P.A., Cattaneo A., Carvalho L.A., Garabedian M.J., Thuret S., et al. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 2011, 16:738-750.
5. Anisman H., Du L., Palkovits M., Faludi G., Kovacs G.G., Szontagh-Kishazi P., et al. Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J Psychiatry Neurosci 2008, 33:131-141.
6. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
7. Bang-Andersen B., Ruhland T., Jørgensen M., Smith G., Frederiksen K., Jensen K.G., et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of mood and anxiety disorders. J Med Chem 2011, 54:3206-3221.
8. Baudry A., Mouillet-Richard S., Schneider B., Launay J.M., Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010, 329:1537-1541.
9. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
10. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
11. Bessa J.M., Ferreira D., Melo I., Marques F., Cerqueira J.J., Palha J.A., et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009, 14:764-773.
12. 11C]WAY-100635. Mol Psychiatry 2004, 9:386-392.
13. Blier P., de Montigny C. Electrophysiological investigations on the effect of zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 1983, 3:1270-1278.
14. 1A agonists in the treatment of depression?. Biol Psychiatry 2003, 53:193-203.
15. Blier P., Gobbi G., Turcotte J.E., de Montigny C., Boucher N., Hébert C., et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009, 19:457-465.
16. Blier P., Ward H.E., Tremblay P., Laberge L., Hébert C., Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010, 167:281-288.
17. Boldrini M., Underwood M.D., Mann J.J., Arango V. Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J Psychiatr Res 2008, 42:433-442.
18. 1A receptor mRNA in chemically identified neurons of the mouse rostral brainstem: implications for the role of serotonin in the regulation of wakefulness and REM sleep. J Comp Neurol 2010, 518:2744-2770.
19. Boothman L., Raley J., Denk F., Hirani E., Sharp T. In vivo evidence that 5-HT2C receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol 2006, 149:861-869.
20. 1A autoreceptors. Mol Psychiatry 2012, 17:567.
21. Brodaty H., Harris L., Peters K., Wilhelm K., Hickie I., Boyce P., et al. Prognosis of depression in the elderly. A comparison with younger patients. Br J Psychiatry 1993, 163:589-596.
22. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004, 161:598-607.
23. Carroll B.J., Cassidy F., Naftolowitz D., Tatham N.E., Wilson W.H., Iranmanesh A., et al. Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand Suppl 2007, 433:90-103.
24. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
25. Cassel S., Carouge D., Gensburger C., Anglard P., Burgun C., Dietrich J.B., et al. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol Pharmacol 2006, 70:487-492.
26. Cole J., Costafreda S.G., McGuffin P., Fu C.H. Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. J Affect Disord 2011, 134:483-487.
27. Coupland N.J., Ogilvie C.J., Hegadoren K.M., Seres P., Hanstock C.C., Allen P.S. Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry 2005, 57:1526-1534.
28. Debonnel G., Saint-André E., Hébert C., de Montigny C., Lavoie N., Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007, 10:51-61.
29. De Deurwaerdère P., Navailles S., Berg K.A., Clarke W.P., Spampinato U. Constitutive activity of the serotonin 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004, 24:3235-3241.
30. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Moreno F.A., et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999, 46:212-220.
31. Delgado P.L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2006, 61(Suppl. 6):7-11.
32. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
33. Dremencov E., El Mansari M., Blier P. Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci 2009, 34:223-229.
34. Dremencov E., El Mansari M., Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 2007, 61:671-678.
35. Drevets W.C., Price J., Furey M.L. Brain and structural and functional abnormalities in mood disorder: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213:93-118.
36. Drevets W.C., Thase M., Moses E., Price J., Frank E., Kupfer D.J., et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007, 34:865-877.
37. Dziedzicka-Wasylewska M., Faron-Górecka A., Kusmider M., Drozdowska E., Rogoz Z., Siwanowicz J., et al. Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology 2006, 31:2424-2432.
38. Fabre V., Beaufour C., Evrard A., Rioux A., Hanoun N., Lesch K.P., et al. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci 2000, 12:2299-2310.
39. Funato H., Kobayashi A., Watanabe Y. Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res 2006, 1117:125-134.
40. Guiard B.P., Chenu F., El Mansari M., Blier P. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. Int J Neuropsychopharmacol 2011, 14:211-223.
41. Guo W.B., Liu F., Xue Z.M., Yu Y., Ma C.Q., Tan C.L., et al. Abnormal neural activities in first-episode, treatment-naïve, short-illness-duration, and treatment-response patients with major depressive disorder: a resting-state fMRI study. J Affect Disord 2011, 135:326-331.
42. Hammar A., Sørensen L., Ardal G., Oedegaard K.J., Kroken R., Roness A., et al. Enduring cognitive dysfunction in unipolar major depression: a test-retest study using the Stroop paradigm. Scand J Psychol 2010, 51:304-308.
43. Hamon M., Bourgoin S. Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects?. Eur Neuropsychopharmacol 2006, 16:S625-S632.
44. Holtzheimer P.E., Mayberg H.S. Deep brain stimulation for psychiatric disorders. Annu Rev Neurosci 2011, 34:289-307.
45. Jacobsen J.P., Siesser W.B., Sachs B.D., Peterson S., Cools M.J., Setola V., et al. Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice. Mol Psychiatry 2012, 17:694-704.
46. Judd L.L., Paulus M.J., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry 2000, 157:1501-1504.
47. Karg K., Burmeister M., Shedden K., Sen S. The serotonin transporter promoter variant(5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011, 68:444-454.
48. Kasper S., Hamon M. Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009, 10:117-126.
49. Kendler K.S., Gatz M., Gardner C.O., Pedersen N.L. A Swedish national twin study of lifetime major depression. Am J Psychiatry 2006, 163:109-114.
50. Kennedy S.H., Evans K.R., Krüger S., Mayberg H.S., Meyer J.H., McCann S., et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001, 158:899-905.
51. Kitaichi Y., Inoue T., Nakagawa S., Boku S., Kakuta A., Izumi T., et al. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 2010, 647:90-96.
52. Koch S., Hemrick-Luecke S.K., Thompson L.K., Evans D.C., Threlkeld P.G., Nelson D.L., et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003, 45:935-944.
53. Kondo H., Saleem K.S., Price J.L. Differential connections of the perirhinal and parahippocampal cortex with the orbital and medial prefrontal networks in macaque monkeys. J Comp Neurol 2005, 493:479-509.
54. Kozel F.A., Rao U., Lu H., Nakonezny P.A., Grannemann B., McGregor T., et al. Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder. Front Psychiatry 2011, 2:1-7.
55. Lanfumey L., Hamon M. 5-HT1 receptors. Curr Drug Targets - CNS Neurol Disord 2004, 3:1-10.
56. Lanfumey L., Mongeau R., Cohen-Salmon C., Hamon M. Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci Biobehav Rev 2008, 32:1174-1184.
57. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
58. Levinson D.F. The genetics of depression: a review. Biol Psychiatry 2006, 60:84-92.
59. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
60. Lira A., Zhou M., Castanon N., Ansorge M.S., Gordon J.A., Francis J.H., et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry 2003, 54:960-971.
61. Lisiecka D., Meisenzahl E., Scheuerecker J., Schoepf V., Whitty P., Chaney A., et al. Neural correlates of treatment outcome in major depression. Int J Neuropsychopharmacol 2011, 14:521-534.
62. Maciag D., Hughes J., O'Dwyer G., Pride Y., Stockmeier C.A., Sanacora G., et al. Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry 2010, 67:465-470.
63. Massart R., Mongeau R., Lanfumey L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci 2012, 367:2485-2494.
64. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
65. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonté B., Szyf M., et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009, 12:342-348.
66. McKinnon M.C., Yucel K., Nazarov A., MacQueen G.M. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009, 34:41-54.
67. Millet B., Vérin M., Drapier D. Psychiatric indications of deep brain stimulation. Bull Acad Natl Med 2010, 194:583-593.
68. Miller H.L., Delgado P.L., Salomon R.M., Berman R., Krystal J.H., Heninger G.R., et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996, 53:117-128.
69. Milner T.A., Lee A., Aicher S.A., Rosin D.L. Hippocampal alpha2a-adrenergic receptors are located predominantly presynaptically but are also found postsynaptically and in selective astrocytes. J Comp Neurol 1998, 395:310-327.
70. Mongeau R., Hamon M., Lanfumey L. How can stress alter emotional balance through its interaction with the serotonergic system?. The handbook of stress: neuropsychological effects on the brain 2011, 480-504. Blackwell Publ. Ltd. C.D. Conrad (Ed.).
71. Mongeau R., Martin C.B., Chevarin C., Maldonado R., Hamon M., Robledo P., et al. 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation Modulation by chronic paroxetine treatment. J Neurochem 2010, 115:438-449.
72. Monteggia L.M., Gideons E., Kavalali E.T. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 2012, [pii: S0006-3223(12)00778-0, Epub ahead of print]. 10.1016/j.biopsych.2012.09.006.
73. 7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011, 36:1275-1288.
74. Montgomery S.A., Henry J., McDonald G., Dinan T., Lader M., Hindmarch I., et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994, 9:47-53.
75. Mørk A., Pehrson A., Brennum L.T., Nielsen S.M., Zhong H., Lassen A.B., et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012, 340:666-675.
76. Narita N., Hashimoto K., Tomitaka S., Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain. Eur J Pharmacol 1996, 307:117-119.
77. Nierenberg A.A., Husain M.M., Trivedi M.H., Fava M., Warden D., Wisniewski S.R., et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010, 40:41-50.
78. Oades R.D., Halliday G.M. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res 1987, 434:117-165.
79. Ongür D., Ferry A.T., Price J.L. Architectonic subdivision of the human orbital and medial prefrontal cortex. J Comp Neurol 2003, 460:425-449.
80. Ordway G.A., Schenk J., Stockmeier C.A., May W., Klimek V. Elevated agonist binding to alpha 2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry 2003, 53:315-323.
81. Owen R.T. Vilazodone: a new treatment option for major depressive disorder. Drugs Today (Barc) 2011, 47:531-537.
82. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001, 50:345-350.
83. Page M.E., Cryan J.F., Sullivan A., Dalvi A., Saucy B., Manning D.R., et al. Behavioral and neurochemical effects of 5-{4-[4-(5-cyano-3indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine 1A receptor partial agonist. J Pharmacol Exp Ther 2002, 302:1220-1228.
84. Paizanis E., Kelai S., Renoir T., Hamon M., Lanfumey L. Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulations. Neurochem Res 2007, 32:1762-1771.
85. 2A receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 2002, 159:419-429.
86. Pariante C.M., Hye A., Williamson R., Makoff A., Lovestone S., Kerwin R.W. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 2003, 28:1553-1561.
87. Pariante C.M., Kim R.B., Makoff A., Kerwin R.W. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 2003, 139:1111-1118.
88. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 1997, 52:571-581.
89. 1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006, 31:1745-1749.
90. Parsey R.V., Oquendo M.A., Ogden R.T., Olvet D.M., Simpson N., Huang Y.Y., et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006, 59:106-113.
91. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995, 25:1171-1180.
92. Pehrson A.L., Cremers T., Bétry C., van der Hart M.G.C., Jørgensen L., Madsen M., et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters - a rat microdialysis and electrophysiological study. Eur Neuropsychopharmacol 2012, 23:133-145.
93. Piñeyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999, 51:533-591.
94. Pitchot W., Hansenne M., Pinto E., Reggers J., Fuchs S., Ansseau M. 5-Hydroxytryptamine 1A receptor, major depression, and suicidal behavior. Biol Psychiatry 2005, 58:854-858.
95. Pitchot W., Wauthy J., Legros J.J., Ansseau M. Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study. Eur Neuropsychopharmacol 2004, 14:151-155.
96. Portella M.J., de Diego-Adeliño J., Ballesteros J., Puigdemont D., Oller S., Santos B., et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011, 72:962-969.
97. Price J.L., Drevets W.C. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 2012, 16:61-71.
98. Rajkowska G., O'Dwyer G., Teleki Z., Stockmeier C.A., Miguel-Hidalgo J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007, 32:471-482.
99. 1B serotonin receptors in adult rat brain. J Comp Neurol 2000, 417:181-194.
100. 1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010, 65:40-52.
101. Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare?. J Clin Psychiatry 2010, 71:1243-1244.
102. Risch N., Herrell R., Lehner T., Liang K.Y., Eaves L., Hoh J., et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009, 301:2462-2471.
103. 3) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 2000, 99:173-181.
104. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168:689-701.
105. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
106. Saleem K.S., Kondo H., Price J.L. Complementary circuits connecting the orbital and medial prefrontal networks with the temporal, insular, and opercular cortex in the macaque monkey. J Comp Neurol 2008, 506:659-693.
107. Sánchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999, 19:467-489.
108. Santamaría J., Tolosa E., Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic Parkinsonism. Neurology 1986, 36:1130-1133.
109. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
110. 1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 1999, 88:899-915.
111. Schramm N.L., McDonald M.P., Limbird L.E. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci 2001, 21:4875-4882.
112. Scorza M.C., Llado-Pelfort L., Oller S., Cortés R., Puigdemont D., Portella M.J., et al. Preclinical and clinical characterization of the selective serotonin-1A receptor antagonist DU-125530 for antidepressant treatment. Br J Pharmacol 2011, 167:1021-1034.
113. Seletti B., Benkelfat C., Blier P., Annable L., Gilbert F., de Montigny C. Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses. Neuropsychopharmacology 1995, 13:93-104.
114. Seminowicz D.A., Mayberg H.S., McIntosh A.R., Goldapple K., Kennedy S., Segal Z., et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 2004, 22:409-418.
115. Shopsin B., Gershon S., Goldstein M., Friedman E., Wilk S. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975, 1:239-249.
116. Shopsin B., Friedman E., Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976, 33:811-819.
117. Shimon H., Agam G., Belmaker R.H., Hyde T.M., Kleinman J.E. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997, 154:1148-1150.
118. Steinbusch H.W. Distribution of serotonin-immunoreactivity in the central nervous system of the rat - cell bodies and terminals. Neuroscience 1981, 6:557-618.
119. Stockmeier C.A., Shapiro L.A., Dilley G.E., Kolli T.N., Friedman L., Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression - postmortem evidence for decreased serotonin activity. J Neurosci 1998, 18:7394-7401.
120. Svenningsson P., Chergui K., Rachleff I., Flajolet M., Zhang X., El Yacoubi M., et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006, 311:77-80.
121. Szabo S.T., Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT2A receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 2002, 302:983-991.
122. Trivedi M.H., Hollander E., Nutt D., Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008, 69:246-258.
123. Turcotte J.E., Debonnel G., de Montigny C., Hébert C., Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001, 24:511-521.
124. Turecki G., Brière R., Dewar K., Antonetti T., Lesage A.D., Séguin M., et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999, 156:1456-1458.
125. Videbech P., Ravkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004, 161:1957-1966.
126. Vincent S., Bieck P.R., Garland E.M., Loghin C., Bymaster F.P., Black B.K., et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 2004, 109:3202-3207.
127. Von Bohlen und Halbach O., Dermietzel R. Neurotransmitters and neuromodulators 2006, Wiley-VCH Verlag GmbH, Weinheim, 386 p.
128. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004, 7:847-854.
129. Westrich L., Pehrson A., Zhong H., Nielsen S.M., Krederiksen K., Stensbol T.B., et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract 2012, 16:47.
130. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
131. Zhang X., Gainetdinov R.R., Beaulieu J.M., Sotnikova T.D., Burch L.H., Williams R.B., et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005, 45:11-16.
132. Zhu X., Wang X., Xiao J., Zhong M., Liao J., Yao S. Altered white matter integrity in first-episode, treatment-naïve young adults with major depressive disorder: a tract-based spatial statistics study. Brain Res 2011, 1369:223-229.
133. 1B receptors. Neuropsychopharmacology 1999, 21(2 Suppl.):52S-60S.